Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2015; 21(43): 12211-12217
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12211
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12211
Gallbladder carcinoma: Prognostic factors and therapeutic options
Thorsten Oliver Goetze, Institut of Clinical Cancer Research, UCT-University Cancer Center Frankfurt, Krankenhaus Nordwest, 60488 Frankfurt, Germany
Author contributions: Goetze TO solely contributed to this paper, who analyzed the data, wrote, revised the manuscript and approved the final manuscript.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Thorsten Oliver Goetze, PD, Institut of Clinical Cancer Research, UCT-University Cancer Center Frankfurt, Krankenhaus Nordwest, Steinbacher Hohl 2-26, 60488 Frankfurt, Germany. thgoetze@aol.com
Telephone: +01577-2527799 Fax: +49-6074-4846206
Received: July 1, 2015
Peer-review started: July 4, 2015
First decision: August 26, 2015
Revised: September 20, 2015
Accepted: October 17, 2015
Article in press: October 20, 2015
Published online: November 21, 2015
Processing time: 139 Days and 21.4 Hours
Peer-review started: July 4, 2015
First decision: August 26, 2015
Revised: September 20, 2015
Accepted: October 17, 2015
Article in press: October 20, 2015
Published online: November 21, 2015
Processing time: 139 Days and 21.4 Hours
Core Tip
Core tip: The outcome of gallbladder carcinoma is poor. In patients with early-stage disease, a 5-year survival rate of 75% is possible. Stage-adjusted therapy is key for improving survival. Despite the theoretical risk factors of gallbladder malignancies, only a third of gallbladder carcinomas are recognized preoperatively, and radical re-resection in cases of incidental discoveries of incidental or occult gallbladder carcinomas is often crucial to complete a so called radical cholecystectomy. Unfortunately, there are diverse interpretations and practices regarding stage-adjusted therapy for gallbladder carcinoma patients. The current data suggest that more radical therapy is warranted.